Price Reductions for 2013 Main Cycle and 2013 Supplementary Cycle A
Price Reductions for 2013 Main Cycle
The outcomes below for the 2013 main cycle are for drugs/manners of administration that were directly affected by the December 2012 Federal Court judgment around treatment of delisted brands in price disclosure. Brands in the 2013 main cycle that were not affected by the December 2012 judgment had outcomes determined in December 2012 with a reduction day on 1 April 2013.
Summary of 1 August 2013 Price Reductions for Main Cycle by Drug / Manner of Administration / Weighted Average Percentage Reduction:
|
Drug |
MOA |
Weighted Average Percentage Reduction |
|---|---|---|
|
Amoxycillin |
Oral |
20.04% |
|
Calcitriol |
Oral |
10.84% |
|
Captopril |
Oral |
24.76% |
|
Carboplatin |
Injection |
22.50% |
|
Carvedilol |
Oral |
23.93% |
|
Cefaclor |
Oral |
11.71% |
|
Cefepime |
Injection |
33.39% |
|
Ceftriaxone |
Injection |
50.18% |
|
Cephalexin |
Oral |
14.14% |
|
Ciprofloxacin |
Oral |
25.17% |
|
Cisplatin |
Injection |
24.02% |
|
Citalopram |
Oral |
37.36% |
|
Clarithromycin |
Oral |
14.49% |
|
Clopidogrel |
Oral |
43.75% |
|
Codeine with paracetamol |
Oral |
13.54% |
|
Enalapril |
Oral |
19.00% |
|
Epirubicin |
Injection/intravesical |
51.35% |
|
Etoposide |
Injection |
34.24% |
|
Famotidine |
Oral |
23.40% |
|
Fluconazole |
Oral |
21.66% |
|
Fluoxetine |
Oral |
18.34% |
|
Fosinopril |
Oral |
10.74% |
|
Gemcitabine |
Injection |
38.58% |
|
Gemfibrozil |
Oral |
18.21% |
|
Irinotecan |
Injection |
27.26% |
|
Lamotrigine |
Oral |
21.40% |
|
Lisinopril |
Oral |
21.13% |
|
Metformin |
Oral |
15.05% |
|
Omeprazole |
Oral |
22.36% |
|
Paroxetine |
Oral |
26.97% |
|
Pravastatin |
Oral |
34.08% |
|
Quinapril |
Oral |
16.36% |
|
Ramipril |
Oral |
20.41% |
|
Risperidone |
Oral |
39.70% |
|
Roxithromycin |
Oral |
20.13% |
|
Sertraline |
Oral |
38.30% |
|
Simvastatin |
Oral |
44.66% |
|
Topiramate |
Oral |
19.20% |
|
Vincristine |
Injection |
27.63% |
For further information about specific weighted average ex-manufacturer price outcomes for each brand, and confirmation of brands with no reductions, please see the legal determination on the Comlaw website.
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is Friday 3 May 2013.
Price Reductions for 2013 Supplementary Cycle A
Summary of 1 August 2013 Price Reductions for 2013 Supplementary Cycle A by Drug / Manner of Administration / Weighted Average Percentage Reduction
|
Drug |
MOA |
Weighted Average Percentage Reduction |
|---|---|---|
|
Dexamethasone |
Injection |
14.46% |
|
Temozolomide |
Oral |
24.43% |
For further information about specific weighted average ex-manufacturer price outcomes for each brand, and confirmation of brands with no reductions, please see the legal determination on the Comlaw website.
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is Friday 3 May 2013.
